New Study: First nationwide evaluation of pathogen patterns and antimicrobial resistance trends among CLABSIs from inpatient oncology settings in more than a decade

Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated, Central Line–Associated Bloodstream Infections From Oncology Settings, 2009–2012

Study Highlights Need for Increased Attention to Infection Control and

Antimicrobial Trends for Cancer Patients

A recent study published online in March by the journal Clinical Infectious Diseases describes central line–associated bloodstream infection (CLABSI) pathogens and antimicrobial resistance patterns reported from oncology locations to the Centers for Disease Control and Prevention's National Healthcare Safety Network (NHSN).

Interestingly, this analysis represents the largest set of data from the United States on pathogens and antimicrobial resistance in oncology and is the first nationwide evaluation of pathogen patterns and antimicrobial trends among BSIs from a hospitalized oncology patient population in more than a decade.

This type of data is important to guide infection prophylaxis and treatment recommendations for inpatient oncology settings.

Read the abstract: http://cid.oxfordjournals.org/content/early/2016/03/23/cid.ciw113.abstract

CDC offers a variety of assessment tools that can help facilities explore potential opportunities for improving antibiotic use. To learn more, visithttp://www.cdc.gov/getsmart/healthcare/implementation.html

For oncology providers in the outpatient setting, CDC developed a variety of resources as part of its Preventing Infections in Cancer Patients program.